Universal Health Services beats by $0.03, beats on revenue - Seeking Alpha

-
[unable to retrieve full-text content]Universal Health Services beats by $0.03, beats on revenue  Seeking Alpha

Universal Health Services (UHS): Q4 Non-GAAP EPS of $2.37 beats by $0.03; GAAP EPS of $1.70 misses by $0.62. Revenue of $2.75B (+4.2% Y/Y) beats by ...



https://ift.tt/2BRrFNd

Comments

Post a Comment

Popular posts from this blog

Robert F. Kennedy Jr., Soon to Announce White House Run, Sows ...

-
Image
standard childhood vaccines :: Article Creator The Vaccines You Need To Know About Before You Travel CNN  —  Few things can ruin a vacation faster than illness. But while a mild stomach bug will probably affect most travelers at some point, there are far more dangerous diseases – including potentially lethal ones – adventurers should know how to protect themselves against. Global concern is mounting over the spread of mpox, a viral illness formerly known as monkeypox, that initially killed 1 in 10 people who contracted it, but now kills up to 3.3%. In August, Sweden became the first country outside the African continent to confirm a case of the newer and more severe mpox strain, clade Ib, which has now also spread to Asia, with a confirmed case in Thailand and suspected cases in Pakistan and the Philippines. The World Health Organization (WHO) has declared the ongoing mpox outbreak across more than a dozen central African nations a ...
Read more

Meningococcal Vaccine: Protection, Risk, Schedule

-
Image
eu astrazeneca :: Article Creator Astellas Claims EU Okay For First Claudin 18.2 Cancer Drug News European Commission The EU has followed Japan and GB in approving Astellas' first-to-market claudin 18.2-targeted therapy Vyloy, clearing it for gastric and gastroesophageal junction (GEJ) cancer. Vyloy (zolbetuximab) has been given the go-ahead for use in combination with chemotherapy for the first-line treatment of adults with locally advanced or metastatic HER2-negative, claudin 18.2-positive gastric or GEJ adenocarcinoma that cannot be treated with surgery. The European Commission's decision comes a few months after the FDA turned down Astellas' marketing application for zolbetuximab in the US because of "unresolved deficiencies" found during an inspection of a third-party manufacturing facility for the antibody. Astellas refiled its US application in May, and a decision is expected in November. Claudin ...
Read more

ZOOM+Care Brings Mental Health Services to the Seattle Area - NBC Right Now

-
Image
SEATTLE , Nov. 6, 2019 /PRNewswire/ --  ZOOM+Care , a leading provider of on-demand healthcare, is expanding its Mental Health service line to include the Seattle area. Eastside Seattle area residents seeking diagnosis, treatment, and medication management can now schedule a Mental Health visit at ZOOM+Care's Bellevue clinic on NE 8th St in Lincoln Square. In December, the company plans to launch a second Bellevue Clinic, dedicated solely to providing Mental Healthcare specialty services. Located at 10541 NE 4th St, it will be the first ZOOM+Care clinic of its kind. The addition of Mental Healthcare services in Seattle furthers Zoom's mission to provide complete, no-wait care. Previously, Mental Health specialty services were only available to ZOOM+Care patients in Portland.  "For years we've been hoping to bring a more complete service offering to our patients in Seattle , and I'm excited that it's coming to fruition," says Erik Vanderlip , ZOO...
Read more